Previous 10 | Next 10 |
home / stock / sny / sny articles
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson&n...
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development program of tusamitamab ravtansine. The decision is ba...
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combine...
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic...
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, ...
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbuster potential (to make over $1 billion in annual sales), ...
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agon...
Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobruti...
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...